Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
Sangamo Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
Sangamo Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
Sangamo Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
Sangamo Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
Sangamo Therapeutics Analyst Ratings
Wells Fargo Downgrades Sangamo, Cites Removal of Key Year-end Catalyst
HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $3
Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target
Sangamo Therapeutics Analyst Ratings
RBC Capital Downgrades Sangamo as Biotech Moves to Save Cash
RBC Capital Downgrades Sangamo Therapeutics to Sector Perform, Lowers Price Target to $2